Cur18 Supplement Projected to Deliver Over $2.5M in Annual Revenue for Cosmos Health
COSM sits 30% above its 52-week low of $0.281 on light trading volume (0.2× avg).
Summary
Cosmos Health projects over $2.5 million in incremental annual revenue from its Cur18 curcumin supplement in the United States within the next 12 to 18 months. This follows the company's April 17th announcement of the planned Q2 2026 U.S. launch for Cur18. For a company with an approximate $18.5 million market capitalization and a recent going concern warning, this projected revenue represents a material positive development. It offers a potential new revenue stream that could help mitigate the company's significant financial challenges, which were highlighted by a recent S-3/A filing for substantial share dilution. Traders will closely watch the actual commercialization progress and sales performance of Cur18 to assess if these projections are realized and contribute meaningfully to the company's financial stability.
At the time of this announcement, COSM was trading at $0.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $18.5M. The 52-week trading range was $0.28 to $1.32. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Access Newswire.